Alteplase

From WikiProjectMed
Jump to navigation Jump to search
Alteplase
Names
Trade namesActivase, Actilyse, others
Other namest-PA, rt-PA
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)[1]
Defined daily dose0.1 gram[2]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Chemical and physical data
FormulaC2569H3928N746O781S40
Molar mass59042.52 g·mol−1
  (verify)

Alteplase (t-PA) is a thrombolytic medication, used to treat acute ST elevation myocardial infarction (a type of heart attacks), pulmonary embolism associated with low blood pressure, acute ischemic stroke, and blocked central venous access devices (CVAD).[3] It is given by injection into a vein or artery.[3]

Common side effects are bleeding including intracranial bleeding and GI bleeding.[3] Other side effects may rarely include allergic reactions.[3] It is not recommended in those allergic to gentamicin.[4] Safety of use in pregnancy is unclear.[1] Alteplase is a manufactured form of tissue plasminogen activator.[3] It works by converting plasminogen to plasmin in a blood clot.[3]

Alteplase was approved for medical use in the United States in 1987.[3][5] It is on the World Health Organization's List of Essential Medicines.[6] In the United Kingdom it costs about £864 per treatment as of 2018.[4] In the United States this amount costs about US$9,197 as of 2019.[7]

Medical uses

Alteplase is mainly used to treat acute ischemic stroke, acute myocardial infarction, acute massive pulmonary embolism, and blocked catheters.[3][8][9] Similar to other thrombolytic drugs, alteplase is used to dissolve clots to restore tissue perfusion, but this can vary depending on the pathology.[10][11][12] Generally, alteplase is delivered intravenously into the body.[13] To treat blocked catheters, alteplase is administered directly into the catheter.[13]

Alteplase has also been used off-label for deep vein thrombosis, peripheral artery disease, pleural effusion in children, prosthetic valve thrombosis, frostbite, and peritonitis.[14][15]

Ischemic stroke

In adults diagnosed with acute ischemic stroke, thrombolytic treatment with alteplase is the standard of care during early management (within 4.5 hours of symptom onset).[11] When mechanical thrombectomy is not available, alteplase may be considered up to 9 hours after symptom onset.[16]

Administration of alteplase is associated with improved functional outcomes and reduced incidence of disability.[14] Alteplase used in conjunction with mechanical thrombectomy is associated with better outcomes.[17] Use is restricted, however, if there is a risk of major bleeding or if there may be another cause of stroke symptoms.[11][18] Alteplase is not recommended for those with non-disabling stroke.[16]

For patients with early recurrent ischemic stroke, repeated use of alteplase may be safe and efficacious.[19]

Alteplase is also commonly used in children, though guidelines are not yet standardized as they are for adults.[20][21]

Heart attack

Currently, the preferred treatment for ST-elevation myocardial infarction (STEMI) is percutaneous coronary intervention (PCI).[10] However, PCI is only available at 25% of hospitals in the United States; alteplase is recommended if the patient is at a non-PCI capable hospital and cannot be transferred to receive PCI in under 120 minutes.[10][22] Alteplase can also be used before arriving at the hospital if transportation time is anticipated to be greater than 30 minutes.[23]

Alteplase may be used in conjunction with aspirin and heparin.[14] An accelerated infusion of alteplase was found to significantly reduce mortality in comparison to a non-accelerated infusion, though it also slightly increases the risk of major bleeding.[24]

Alteplase should not be used in cases of acute coronary syndrome other than STEMI.[23]

Pulmonary embolism

As of 2019, alteplase is the most commonly used medication to treat pulmonary embolism (PE).[25] Alteplase has a short infusion time of 2 hours and a half-life of 4–6 minutes.[25] Alteplase has been approved by the FDA, and treatment can be done via systemic thrombolysis or catheter-directed thrombolysis.[25][26]

Systemic thrombolysis can quickly restore right ventricular function, heart rate, and blood pressure in patients with acute PE.[27] However, standard doses of alteplase used in systemic thrombolysis may lead to massive bleeding, such as intracranial hemorrhage, particularly in older patients.[25] A systematic review has shown that that low-dose alteplase is safer than and as effective as the standard amount.[28]

Catheter-directed thrombolysis may be more efficient than systemic thrombolysis, as alteplase is locally administered to the occlusion site, and wash-away of the medication into other blood vessels is minimized.[27] This procedure involves positioning a multi-sidehole catheter into the blood clot.[27]

Alteplase may be used to treat PE if patients have a high risk for complications, such as if:[29]

Blocked catheters

Alteplase can be used in small doses to clear blood clots that obstruct a catheter, reopening the catheter so it can continue to be used.[9][14] Catheter obstruction is commonly observed with a central venous catheter.[32] Currently, the standard treatment for catheter obstructions in the United States is alteplase administration.[33] Alteplase is effective and low risk for treating blocked catheters in adults and children.[33][32] Overall, adverse effects of alteplase for clearing blood clots are rare.[34] Novel alternatives to treat catheter occlusion, such as tenecteplase, reteplase, and recombinant urokinase, offer the advantage of shorter dwell times than alteplase.[32]

Dosage

The defined daily dose is 0.1 gram (by injection).[2]

Contraindications

A person should not receive alteplase treatment if testing shows they are not suffering from an acute ischemic stroke or if the risks of treatment outweigh the likely benefits.[11] Alteplase is contraindicated in those with bleeding disorders that increase a person's tendency to bleed and in those with an abnormally low platelet count.[18] Active internal bleeding and high blood pressure are additional contraindications for alteplase.[18] The safety of alteplase in the pediatric population has not been determined definitively.[18] Additional contraindications for alteplase when used specifically for acute ischemic stroke include current intracranial hemorrhage and subarachnoid hemorrhage.[35] Contraindications for use of alteplase in people with a STEMI are similar to those of acute ischemic stroke.[10] People with an acute ischemic stroke may also receive other therapies including mechanical thrombectomy.[11]

Side effects

Given that alteplase is a thrombolytic medication, a common side effect is bleeding, which can be life threatening.[36] Adverse effects of alteplase include symptomatic intracranial hemorrhage and fatal intracranial hemorrhage.[36]

Angioedema is another adverse effect of alteplase, which can be life-threatening if the airway becomes obstructed.[8] Other side effects may rarely include allergic reactions.[3] Alteplase is a pregnancy category C drug.[1]

Mechanism of action

Depiction of the pathway that alteplase (t-PA) uses to promote the degradation of a blood clot (fibrin).

Alteplase binds to fibrin in a blood clot and activates the clot-bound plasminogen.[13] Alteplase cleaves plasminogen at the site of its Arg561-Val562 peptide bond to form plasmin.[13] Plasmin is a fibrinolytic enzyme that cleaves the cross-links between polymerized fibrin molecules, causing the blood clot to break down and dissolve, a process called fibrinolysis.[13]

Regulation and inhibition

Plasminogen activator inhibitor 1 stops alteplase activity by binding to it and forming an inactive complex, which is removed from the bloodstream by the liver.[13] Fibrinolysis by plasmin is extremely short-lived due to plasmin inhibitors, which inactivate and regulate plasmin activity.[13]

History

FDA approval

Alteplase was approved for medical use in the United States in November 1987 for the treatment of myocardial infarction.[3][8][37][38] This was just seven years after the first efforts were made to produce recombinant t-PA, making it one of the fastest drug developments in history.[38]

In 1995, a study by the National Institute of Neurological Disorders and Stroke showed the effectiveness of administering intravenous alteplase to treat ischemic stroke.[39] This sparked a medical paradigm shift as it redesigned stroke treatment in the emergency department to allow for timely assessment and therapy for ischemic stroke patients.[39]

Commercialization

Commercialization and large scale manufacture of human t-PA has been made possible through the generation of Chinese hamster ovary cells, which are capable of producing alteplase (recombinant human t-PA) with the use of recombinant DNA technology.[40] Brands include Activase and Cathflo Activase, marketed by Genentech Inc. in the US, and Actilyse, marketed by Boehringer Ingelheim in Germany.[9][40]

Society and culture

Alteplase was added to the World Health Organization's List of Essential Medicines in 2019, for use in ischemic stroke.[41][42]

As early use of alteplase is important for ischemic stroke, treatment delay is a serious concern.[43] Many reasons for delay exist, including lack of access to healthcare, late presentation, late assessment, misdiagnosis, and management of comorbidities.[43]

Alteplase is extremely underused in low- and middle-income countries.[44] This may be due to its high cost and the fact that it is often not covered by health insurance.[44]

There may be citation bias in the literature on alteplase in ischemic stroke, as studies reporting positive results for tissue plasminogen activator are more likely to be cited in following studies than those reporting negative or neutral results.[45]

There is a sex difference in the use of intravenous tissue plasminogen activator, as it is less likely to be used for women with acute ischemic stroke than men.[46] However, this difference has been improving since 2008.[46]

Economics

The cost of alteplase in the United States increased by 111% between 2005 and 2014, despite there being no proportional increase in the costs of other prescription drugs.[47] However, alteplase continues to be cost-effective.[47]

Brand names

Alteplase is marketed as Actilyse, Activase, and Cathflo or Cathflo Activase.[40][48]

References

  1. 1.0 1.1 1.2 "Alteplase Use During Pregnancy". Drugs.com. Retrieved 12 November 2019. CS1 maint: discouraged parameter (link)
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 10 September 2020. CS1 maint: discouraged parameter (link)
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 "Alteplase Monograph for Professionals". Drugs.com. Retrieved 11 November 2019. CS1 maint: discouraged parameter (link)
  4. 4.0 4.1 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 216. ISBN 9780857113382.
  5. "Activase: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 4 January 2020.
  6. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. "Activase Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 November 2019. CS1 maint: discouraged parameter (link)
  8. 8.0 8.1 8.2 "Activase- alteplase kit". DailyMed. 5 December 2018. Archived from the original on 11 January 2017. Retrieved 4 January 2020.
  9. 9.0 9.1 9.2 "Cathflo Activase- alteplase injection, powder, lyophilized, for solution". DailyMed. 6 September 2019. Archived from the original on 29 January 2021. Retrieved 14 November 2020.
  10. 10.0 10.1 10.2 10.3 O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. (January 2013). "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. 127 (4): e362-425. doi:10.1161/CIR.0b013e3182742cf6. PMID 23247304.
  11. 11.0 11.1 11.2 11.3 11.4 Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. (December 2019). "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. 50 (12): e344–e418. doi:10.1161/STR.0000000000000211. PMID 31662037.
  12. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. (March 2018). "2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. 49 (3): e46–e110. doi:10.1161/STR.0000000000000158. PMID 29367334.
  13. 13.0 13.1 13.2 13.3 13.4 13.5 13.6 Jilani TN, Siddiqui AH (April 2020). "Tissue Plasminogen Activator". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 29939694. Archived from the original on 29 January 2021. Retrieved 2020-11-10.
  14. 14.0 14.1 14.2 14.3 Reed M, Kerndt CC, Nicolas D (2020). "Alteplase". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 29763152. Archived from the original on 29 January 2021. Retrieved 2020-10-30.
  15. Hughes RE, Tadi P, Bollu PC (2020). TPA Therapy. Treasure Island: StatPearls.
  16. 16.0 16.1 Powers WJ (July 2020). Solomon CG (ed.). "Acute Ischemic Stroke". The New England Journal of Medicine. 383 (3): 252–260. doi:10.1056/NEJMcp1917030. PMID 32668115.
  17. Mistry EA, Mistry AM, Nakawah MO, Chitale RV, James RF, Volpi JJ, Fusco MR (September 2017). "Mechanical Thrombectomy Outcomes With and Without Intravenous Thrombolysis in Stroke Patients: A Meta-Analysis". Stroke. 48 (9): 2450–2456. doi:10.1161/STROKEAHA.117.017320. PMID 28747462. S2CID 3751956.
  18. 18.0 18.1 18.2 18.3 Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al. (February 2016). "Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. 47 (2): 581–641. doi:10.1161/STR.0000000000000086. PMID 26696642. S2CID 9381101.
  19. Sarmiento RJ, Diestro JD, Espiritu AI, San Jose MC (October 2019). "Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review". Journal of Stroke and Cerebrovascular Diseases. 28 (10): 104290. doi:10.1016/j.jstrokecerebrovasdis.2019.07.006. PMID 31371140.
  20. Tarango C, Manco-Johnson MJ (December 2017). "Pediatric Thrombolysis: A Practical Approach". Frontiers in Pediatrics. 5: 260. doi:10.3389/fped.2017.00260. PMC 5723643. PMID 29270396.
  21. Rivkin MJ, deVeber G, Ichord RN, Kirton A, Chan AK, Hovinga CA, et al. (March 2015). "Thrombolysis in pediatric stroke study". Stroke. 46 (3): 880–5. doi:10.1161/STROKEAHA.114.008210. PMC 4342311. PMID 25613306.
  22. Gurman P, Miranda OR, Nathan A, Washington C, Rosen Y, Elman NM (March 2015). "Recombinant tissue plasminogen activators (rtPA): a review". Clinical Pharmacology and Therapeutics. 97 (3): 274–85. doi:10.1002/cpt.33. PMID 25670034. S2CID 19937661.
  23. 23.0 23.1 Marchand DK, Farrah K (July 2019). Thrombolytics for Acute Myocardial Infarction in a Pre-Hospital Setting: A Review of Comparative Safety and Guidelines (PDF). CADTH (Report). Archived (PDF) from the original on 20 October 2019. Retrieved 12 November 2020.
  24. Jinatongthai P, Kongwatcharapong J, Foo CY, Phrommintikul A, Nathisuwan S, Thakkinstian A, et al. (August 2017). "Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis". Lancet. 390 (10096): 747–759. doi:10.1016/s0140-6736(17)31441-1. PMID 28831992. S2CID 23933674.
  25. 25.0 25.1 25.2 25.3 Ucar EY (June 2019). "Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism". The Eurasian Journal of Medicine. 51 (2): 186–190. doi:10.5152/eurasianjmed.2019.19291. PMC 6592452. PMID 31258361.
  26. Martin C, Sobolewski K, Bridgeman P, Boutsikaris D (December 2016). "Systemic Thrombolysis for Pulmonary Embolism: A Review". P & T. 41 (12): 770–775. PMC 5132419. PMID 27990080.
  27. 27.0 27.1 27.2 Engelberger RP, Kucher N (March 2014). "Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review". European Heart Journal. 35 (12): 758–64. doi:10.1093/eurheartj/ehu029. PMID 24497337.
  28. Zhang Z, Zhai ZG, Liang LR, Liu FF, Yang YH, Wang C (March 2014). "Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis". Thrombosis Research. 133 (3): 357–63. doi:10.1016/j.thromres.2013.12.026. PMID 24412030.
  29. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW (August 2004). "Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials". Circulation. 110 (6): 744–9. doi:10.1161/01.CIR.0000137826.09715.9C. PMID 15262836. S2CID 7663879.
  30. 30.0 30.1 "Management of PE". American College of Cardiology. January 2020. Archived from the original on 28 November 2020. Retrieved 2020-10-30.
  31. 31.0 31.1 Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. (February 2016). "Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report". Chest. 149 (2): 315–352. doi:10.1016/j.chest.2015.11.026. PMID 26867832.
  32. 32.0 32.1 32.2 Baskin JL, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, Pui CH, Howard SC (May 2012). "Thrombolytic therapy for central venous catheter occlusion". Haematologica. 97 (5): 641–50. doi:10.3324/haematol.2011.050492. PMC 3342964. PMID 22180420.
  33. 33.0 33.1 Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, Howard SC (July 2009). "Management of occlusion and thrombosis associated with long-term indwelling central venous catheters". Lancet. 374 (9684): 159–69. doi:10.1016/S0140-6736(09)60220-8. PMC 2814365. PMID 19595350.
  34. Hilleman D, Campbell J (October 2011). "Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review". Pharmacotherapy. 31 (10): 1031–40. doi:10.1592/phco.31.10.1031. PMID 21950645. S2CID 2092899.
  35. Parker S, Ali Y (October 2015). "Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS". Current Cardiology Reports. 17 (10): 81. doi:10.1007/s11886-015-0633-5. PMID 26277361. S2CID 26427160.
  36. 36.0 36.1 Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. (November 2014). "Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials". Lancet. 384 (9958): 1929–35. doi:10.1016/S0140-6736(14)60584-5. PMC 4441266. PMID 25106063.
  37. "Activase: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 27 August 2020. Retrieved 4 January 2020.
  38. 38.0 38.1 Collen D, Lijnen HR (August 2009). "The tissue-type plasminogen activator story". Arteriosclerosis, Thrombosis, and Vascular Biology. 29 (8): 1151–5. doi:10.1161/ATVBAHA.108.179655. PMID 19605778. Archived from the original on 29 January 2021. Retrieved 16 November 2020.
  39. 39.0 39.1 Campbell BC, Meretoja A, Donnan GA, Davis SM (August 2015). "Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability". Stroke. 46 (8): 2341–6. doi:10.1161/STROKEAHA.114.007564. PMID 26152294.
  40. 40.0 40.1 40.2 Collen D, Lijnen HR (April 2004). "Tissue-type plasminogen activator: a historical perspective and personal account". Journal of Thrombosis and Haemostasis. 2 (4): 541–6. doi:10.1111/j.1538-7933.2004.00645.x. PMID 15102005. S2CID 42654928.
  41. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  42. World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
  43. 43.0 43.1 Sharobeam A, Jones B, Walton-Sonda D, Lueck CJ (March 2020). "Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature". Journal of Neurology. doi:10.1007/s00415-020-09803-6. PMID 32206899. S2CID 214606658.
  44. 44.0 44.1 Khatib R, Arevalo YA, Berendsen MA, Prabhakaran S, Huffman MD (2018). "Presentation, Evaluation, Management, and Outcomes of Acute Stroke in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis". Neuroepidemiology. 51 (1–2): 104–112. doi:10.1159/000491442. PMC 6322558. PMID 30025394.
  45. Misemer BS, Platts-Mills TF, Jones CW (September 2016). "Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis". Trials. 17 (1): 473. doi:10.1186/s13063-016-1595-7. PMC 5039798. PMID 27677444. S2CID 9343300.
  46. 46.0 46.1 Strong B, Lisabeth LD, Reeves M (July 2020). "Sex differences in IV thrombolysis treatment for acute ischemic stroke: A systematic review and meta-analysis". Neurology. 95 (1): e11–e22. doi:10.1212/wnl.0000000000009733. PMID 32522796. S2CID 219586256.
  47. 47.0 47.1 Kleindorfer D, Broderick J, Demaerschalk B, Saver J (July 2017). "Cost of Alteplase Has More Than Doubled Over the Past Decade". Stroke. 48 (7): 2000–2002. doi:10.1161/strokeaha.116.015822. PMID 28536176. S2CID 3729672.
  48. "Cathflo Activase Uses, Side Effects & Warnings". Drugs.com. Archived from the original on 22 September 2020. Retrieved 2020-11-16.

External links